Swedish Pharma Stock News

Embracer Group has completed the spin off and public listing of Coffee Stain Group, marking a refocus on core IP and tighter operational discipline. The company reports improved profitability, supported by key releases such as Kingdom Come: Deliverance II. OM:EMBRAC B last closed at SEK57.68, following a 23.9% return over the past week and 11.4% over the past month. For you as an investor, the Coffee Stain spin off signals that Embracer Group is reshaping its business around its own...

Camurus (OM:CAMX) has rounded out FY 2025 with Q4 revenue of SEK 464.5 million and basic EPS of SEK 1.69, while its trailing twelve month revenue sits at SEK 2.3 billion and EPS at SEK 12.42, reflecting the earnings growth investors have been watching. Over the past year, the company has seen revenue move from SEK 1.9 billion and EPS of SEK 7.39 on a trailing basis at Q4 2024 to SEK 2.3 billion and EPS of SEK 12.42 by Q4 2025, alongside net income of SEK 735.6 million. This sets a clear...

Hexagon (OM:HEXA B) is back in focus after its Manufacturing Intelligence business supplied advanced metrology and digitalisation tools for Red Bull Ford Powertrains' first Formula 1 power unit developed under stringent new regulations. See our latest analysis for Hexagon. Despite the high profile Formula 1 partnership, Hexagon's recent trading has been weak, with the share price at SEK97.66 after a 30 day share price return decline of 8.69% and a 12 month total shareholder return decline of...

Earnings and dividend announcement set the scene Invisio (OM:IVSO) has just combined its fourth quarter 2025 results with a declared annual dividend of SEK 3.00 per share, a pairing that naturally focuses attention on cash generation and shareholder returns. See our latest analysis for Invisio. The strong fourth quarter report, followed by the SEK 3.00 dividend announcement, has coincided with a sharp pick up in near term optimism, with a 7 day share price return of 26.8% and a 3 year total...

BioArctic (OM:BIOA B) is back in focus after partner Eisai secured Priority Review in China for a subcutaneous Leqembi autoinjector, while recent Leqembi driven royalties to BioArctic grew sharply year on year. See our latest analysis for BioArctic. BioArctic’s partner driven Leqembi news arrives as the share price sits at SEK322.2, with a 5.02% 7 day share price return, a 6.01% 30 day share price decline and a 51.69% 1 year total shareholder return, which points to momentum that has cooled...

Saab (OM:SAAB B) just signed a Memorandum of Understanding with Ukrainian Defense Industry at the Munich Security Conference, targeting cooperation in aviation and airborne surveillance to support Ukraine’s defence capabilities. See our latest analysis for Saab. That Munich Security Conference MoU arrives after a busy start to the year, with Saab reporting higher full year 2025 sales and earnings and proposing a higher dividend. The 90 day share price return of 21.56% and a very large 5 year...

Vimian Group (OM:VIMIAN) FY 2025 Earnings Snapshot Vimian Group (OM:VIMIAN) has just closed FY 2025 with Q4 revenue of €110 million and basic EPS of €0.23, setting the tone for a year where trailing twelve month revenue reached €428.3 million and EPS came in at €0.06. Over recent quarters, the company has seen revenue move from €104.3 million in Q2 2025 to €107.5 million in Q1 2025 and €104.3 million in Q3 2025. Quarterly EPS ranged from €0.01 to €0.02 before stepping up to €0.23 in Q4,...

Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...

Despite the fact that Elicera Therapeutics AB (publ)'s (STO:ELIC) value has dropped 11% in the last week insiders who...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Lime Technologies (OM:LIME) has wrapped up FY 2025 with fourth quarter revenue of SEK 201.1 million and basic EPS of SEK 2.41, giving investors a fresh data point on both top line scale and per share profitability. The company has seen quarterly revenue move from SEK 185.3 million in Q4 2024 to SEK 201.1 million in Q4 2025, while basic EPS over the same quarters shifted from SEK 1.82 to SEK 2.41. This sits alongside trailing twelve month EPS of SEK 8.40 on revenue of SEK 747.4 million and...

MedCap AB (publ) ( STO:MCAP ) shareholders might be concerned after seeing the share price drop 12% in the last week...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Last week, you might have seen that Mips AB (publ) ( STO:MIPS ) released its full-year result to the market. The early...

Nodebis Applications AB (publ)'s ( NGM:NODE ) periodic dividend will be increasing on the 27th of May to SEK1.50, with...

Last week, you might have seen that Storytel AB (publ) ( STO:STORY B ) released its full-year result to the market. The...

There's been a notable change in appetite for Boule Diagnostics AB (publ) ( STO:BOUL ) shares in the week since its...

The market shrugged off AVTECH Sweden AB (publ)'s ( STO:AVT B ) solid earnings report. We think that investors might be...

Instalco (OM:INSTAL) FY 2025 headline numbers set the tone Instalco (OM:INSTAL) has wrapped up FY 2025 with fourth quarter revenue of SEK3.8b and basic EPS of SEK0.49, putting concrete numbers around the company’s latest trading update. The company has seen quarterly revenue range from SEK3.0b to SEK3.8b through 2025, while basic EPS has moved between SEK0.19 and SEK0.49. This gives investors a clear view of how the top line and per share earnings have tracked through the year. With trailing...

Coor Service Management Holding AB's ( STO:COOR ) dividend will be increasing from last year's payment of the same...

How C-Rad (OM:CRAD B) Finished FY 2025 C-Rad (OM:CRAD B) closed out FY 2025 with fourth quarter revenue of 105.8 million SEK and EPS of 0.05 SEK, capping a year where trailing 12 month revenue came in at 441.9 million SEK and EPS at 0.31 SEK. Over recent periods the company has seen quarterly revenue move between 100.1 million SEK and 121.5 million SEK, while EPS has ranged from a loss of 0.24 SEK in early 2025 to 0.43 SEK in late 2024. This sets the scene for investors to weigh forecast...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Polygiene Group AB ( STO:POLYG ) shareholders won't be pleased to see that the share price has had a very rough month...

Heba Fastighets AB (publ) ( STO:HEBA B ) will increase its dividend from last year's comparable payment on the 30th of...